Swiss Lions 100 | 2026 edition
Sandoz
Sandoz is No. 32 in the Swiss Lions 100 and No. 5 in Life Sciences & Health, with a score of 54.5 out of 100. Headquarters: Basel, canton of Basel-Stadt.
- Swiss Lions score
- 54.5
- Overall rank
- 32of 100
- Life Sciences & Health
- 5of 14
About
Basel-based maker of generic medicines and biosimilars. It was spun off from Novartis in 2023.
How the score is made
Global scale
CHF 7.8bn revenue.
Swiss value
Swiss made: Limited.
Prominence
Online attention across languages, and worldwide search interest.
Impact
Near-term target validated. Not a certified B Corp.
Philanthropy
Corporate foundation: Fondation Edouard et Maurice Sandoz.
Key figures
- Revenue used in the ranking
- CHF 7.8bnTTM Oct 2026, company
- Revenue
- USD 11.7bnTwelve months to 30 June 2026
- Net profit
- USD 646mAttributable to shareholders
- Dividends paid
- USD 445mTo all shareholders
- Employees worldwide
- 20,000
Employees in Switzerland and dividends paid to Swiss shareholders are not published consistently, so they are not shown.
Profile
- Headquarters
- BaselCanton of Basel-Stadt
- Language region
- German-speaking
- Category
- Life Sciences & Health
- Ownership
- Listed
- Main customers
- Businesses (B2B)
- Chief executive
- Richard SaynorSince 2019. Source
- Founded
- 1886
Nearby in the Swiss Lions 100
Also in Life Sciences & Health
1RocheScore 80.8
2NovartisScore 78.6
3LonzaScore 59.5
4SonovaScore 54.8
6StraumannScore 53.5
7FerringScore 48.4
See all 14 brands in Life Sciences & Health.
Sources
- Revenue used in the ranking: stockanalysis.com SDZ (TTM Oct 2026).
- Revenue, net profit, dividends and employees: stockanalysis.com, from company filings.
- Climate target: Science Based Targets initiative dashboard, October 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or Sandoz can publish figures for the next edition, tell us. Corrections are recorded with their source.